KDM6A and myeloid leukemia: Here, in agreement with previous findings, we provide initial evidence that GSKJ4 compound increases the global level of H3K27me2/3 methylation and acts as a small molecule inhibitor of the proliferation of myeloid leukemia cells, mechanistically suggesting that GSKJ4 might have anticancer activity by inhibiting demethylases JMJD3 and UTX.